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Experimental autoimmune encephalomyelitis
Inhibition of phospholipase A2 (PLA2) has recently been found to attenuate the pathogenesis of experimental
autoimmune encephalomyelitis (EAE), a commonly used animal model of multiple sclerosis (MS). However,
the protective mechanisms that underlie PLA2 inhibition are still not well understood. In this study, we found
that cytosolic PLA2 (cPLA2) was highly expressed in infiltrating lymphocytes and macrophages/microglia in
mouse spinal cord white matter. Although cPLA2 is also expressed in spinal cord neurons and
oligodendrocytes, there were no differences observed in these cell types between EAE and control animals.
Arachidonyl trifluoromethyl ketone (AACOCF3), a cPLA2 inhibitor, significantly reduced the clinical symptoms
and inhibited the body weight loss typically found in EAE mice. AACOCF3 also attenuated the loss of mature,
myelin producing, oligodendrocytes, and axonal damage in the spinal cord white matter. Nitrotyrosine
immunoreactivity, an indicator of peroxynitrite formation, was dramatically increased in EAE mice and
attenuated by treatment with AACOCF3. These protective effects were not evident when AA861, an inhibitor
of lipoxygenase, was used. In primary cultures of microglia, lipopolysaccharide (LPS) induced an upregulation
of cPLA2, inducible nitric oxide synthase (iNOS) and components of the NADPH oxidase complex, p47phox
and p67phox. AACOCF3 significantly attenuated iNOS induction, nitric oxide production and the generation of
reactive oxygen species in reactive microglia. Similar to the decomposition catalyst of peroxynitrite, AACOCF3
also blocked oligodendrocyte toxicity induced by reactive microglia. These results suggest that AACOCF3 may
prevent oligodendrocyte loss in EAE by attenuating peroxynitrite formation in the spinal cord white matter.
Published by Elsevier Inc.
Introduction
Experimental autoimmune encephalomyelitis (EAE) is a well
recognized animal model for multiple sclerosis (MS), which is
characterized by lymphocyte infiltration, macrophages/microglia
activation, demyelination, oligodendrocyte (OL) loss and axonal
injury (Bjartmar et al., 2003; Furlan et al., 2009; Lassmann, 2010;
Steinman and Zamvil, 2006). Although a number of pharmacological
agents have shown promise in the treatment of EAE, the pathogenic
mechanisms of MS/EAE and the therapeutic targets of the drugs'
action are still not well understood.
Activation of phospholipase A2 (PLA2) has recently emerged as an
important initiator in the pathogenesis of many inflammatory and
neurodegenerative diseases, including MS and Alzheimer's disease
(Farooqui et al., 2006; Sanchez-Mejia et al., 2008; Shelat et al., 2008).
PLA2 occurs as three isozymes. These isoforms include calcium-
dependent cytosolic PLA2 (cPLA2), secretory PLA2 (sPLA2) and
calcium-independent PLA2 (iPLA2) (Farooqui and Horrocks, 2006;
Kudo and Murakami, 2002). Of the three PLA2 isoforms, cPLA2
preferentially hydrolyzes phospholipids containing arachidonic
acids (Kita et al., 2006; Kudo and Murakami, 2002) and plays a key
role in the biosynthesis of prostaglandins and leukotrienes via
activation of cyclooxygenase (COX) and lipoxygenase (LOX), respec-
tively (Funk, 2001). Although several COX inhibitors have been shown
to ameliorate EAE (Muthian et al., 2006; Ni et al., 2007), the severe
side effects caused by these inhibitors, such as gastrointestinal ulcers
triggered by indomethacin (Miyamoto et al., 2006) and the cardio-
vascular risk induced by rofecoxib (Juni et al., 2004), suggest that COX
inhibitors might not be practically useful for the treatment of MS
(James et al., 2007). Considering the fact that inhibition of COX can
shift the arachidonic acid metabolism from the COX pathway to the
LOX pathway, it is possible that inhibitors of LOX or the combined
inhibition of PLA2 and LOX could directly lead to better therapeutic
outcomes.
We have previously shown that peroxynitrite, the toxic species
released from reactive microglia (Li et al., 2005), causes OL toxicity by
activation of 12-LOX (Zhang et al., 2006). Since the production of
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arachidonic acid from membrane phospholipids catalyzed by cPLA2 is
the rate-limiting step for the subsequent 12-LOX metabolism,
blocking cPLA2 and LOX activation may prevent OL toxicity in an
animal model of MS. Using myelin oligodendrocyte glycoprotein
(MOG) 35–55 peptide-induced EAE mouse model, we found that
AACOCF3, a cPLA2 inhibitor, but not AA861, a LOX inhibitor,
ameliorates the clinical signs of EAE. The protective mechanisms of
AACOCF3 might be due to its improvement of blood–brain barrier
function and its inhibition of peroxynitrite formation in EAE mouse
spinal cord white matter.
Materials and methods
Materials
AACOCF3 was obtained from Cayman Chemical Co. (Ann Arbor,
MI). Fe (III) tetrakis(1-methyl-4-pyridyl) porphyrin pentachloride-
porphyrin pentachloride (FeTMPyP) was obtained from Calbiochem
(San Diego, CA). 2′,7′-dichlorohydrofluorescein diacetate (DCF) was
purchased from Molecular Probes, Inc. (Eugene, OR). All the culture
materials were purchased from Gibco Life Technologies (Grand Island,
NY). Platelet-derived growth factor (PDGF), basic fibroblast growth
factor (bFGF), and ciliary neurotrophic factor (CNTF) were purchased
from Peprotech (Princeton, NJ). All other reagents were obtained from
Sigma (St. Louis, MO).
Mice
Female 7-week-old C57Bl/6J mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). Animal care and experimental
procedures were carried out in accordance with NIH guidelines and
approved by the Uniformed Services University Animal Care and Use
Committee.
Induction and clinical evaluation of EAE
EAEwas induced by subcutaneous injection of 200 μg ofMOG35–55
peptide emulsified in Complete Freunds Adjuvant (CFA, DIFCO) with
500 μg Mycobacterium tuberculosis (DIFCO). Immediately following
MOG peptide injection, and 24 h later, mice were administered 200 ng
pertusis toxin (List Biological Labs) intraperitoneally (i.p.). At 1 week
after induction, EAE mice received a booster of 200 μg of MOG in
incomplete Freund's Adjuvant without Mycobacterium tuberculosis.
Animals were monitored blindly and daily by two independent
observers and neurological signs were assessed as follows: 0, normal
mouse; 1, piloerection, tail weakness; 2, tail paralysis; 3, tail paralysis
plushindlimbweakness/paralysis; 4, tail, hindand fore limbparalysis; 5,
moribund/death, using incrementsof 0.5 points for intermediate clinical
findings. The onset of EAEwas defined as thefirst day an animal showed
a clinical score ≥0.5.
Drug treatment
EAE and control mice were randomly assigned to receive AACOCF3
(4 mM, Cayman), a cPLA2 inhibitor; AA861 (4 mM, Sigma), a LOX
inhibitor; AACOCF3 plus AA861; or vehicle (1% DMSO in PBS). There
were 6 animals in each group. Drug treatments were given at day 7
post-immunization (i.p.) daily until day 28. A second set of
experiments were similarly designed, except for the animals were
sacrificed at day 14 post-immunization for assessing the inflamma-
tory response in the spinal cord white matter of EAE with/without
treatments.
Immunohistochemistry (IHC)
Animals were euthanized using a combination of ketamine and
xylazine solution (90 mg ketamine/10 mg xylazine per ml, i.p.), then
intracardially perfusedwith ice cold 1 Mphosphate buffer followed by
4% paraformaldehyde (Sigma, St. Louis, MO) in 1 M phosphate buffer.
Spinal cords were dissected out prior to post-fixation in 4%
paraformaldehyde at 4 °C overnight. Tissue was then cryoprotected
in 30% sucrose (Sigma) in 1 M phosphate buffer at 4 °C overnight.
After being cryoprotected the tissue was embedded in Tissue Tek OCT
(Sakura, Torrance, CA) and stored at −80 °C until utilization.
Transverse sections of lumbar spinal cords were cut at 14 μm with a
cryostat (Leica model CM1900, Bannockburn, IL) and mounted onto
Superfrost Plus slides (Fisher, Pittsburgh, PA) for immunohistological
analysis. To determine the cell type specific expression of cPLA2, 5-
LOX and 12-LOX, we performed double immunostaining using
polyclonal antibodies against cPLA2 (Santa Cruz Biotechnology,
Santa Cruz, CA), 5-LOX and 12-LOX (Cayman Chemicals, Ann Arbor,
MI), and monoclonal antibodies against CC1 (Calbiochem, San Diego,
CA), NeuN (Millipore, Billerica, MA), OX52 (Abcam, Cambridge, MA)
and Mac1 (Millipore, Billerica, MA), markers for mature OLs, neurons,
T-lymphocytes and macrophages/microglia, respectively. Nitrotyro-
sine reactivity in spinal cord white matter was examined using a
polyclonal anti-nitrotyrosine antibody (Millipore, Billerica, MA).
Neurofilaments were labeled with NF-200 (Millipore, Billerica, MA).
SMI-32 (Abcam, Cambridge, MA) was used to label the depho-
sphorylated neurofilaments, indicative of demyelination and axonal
injury (Trapp et al., 1998). Beta-amyloid precursor protein (β-APP)
was also used to detect the degenerated axons. Activated leukocyte
cell adhesionmolecule (ALCAM) and intercellular adhesionmolecule-
1 (ICAM-1) were detected with anti-ALCAM and anti-ICAM polyclonal
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
Cell cultures
Primary cultures of microglia and OLs were prepared from the
cerebral hemispheres of Sprague–Dawley rats at postnatal day 2 using
a selective detachment procedure as previously described (Wang
et al., 2004; Zhang et al., 2006). Briefly, forebrains free of meninges
were dissected out and digested with Hank's balanced salt solution
(HBSS) containing 0.01% trypsin and 10 mg/ml DNase. After centri-
fugation and trituration with the plating medium DMEM20S contain-
ing DMEM, 20% fetal bovine serum, and 1% penicillin–streptomycin,
cells were plated onto polylysine coated 75-cm2 flasks at a density of 1
pup brain per flask. Cultures were fed with fresh DMEM20S medium
every other day for 10–11 days at 37 °C in a humid atmosphere of 5%
CO2/95% air. Microglia were isolated by gently shaking the flask
containing the mixed glial culture for 1 h at 200 rpm at 37 °C. The
mediumwas removed, andmicroglia were collected by centrifugation
at 800 ×g for 5 min. Isolated microglia were plated into 24-well
(5×104 per well) or 96-well (1×104 per well) plates and exper-
iments were performed in the next 2 days. The purity of the microglia
cultures was consistently N95%.
After removing microglia, the flasks were then changed to new
media and shaken overnight. The OL progenitor cells were detached
from the astrocyte layer and were resuspended and seeded onto poly-
ornithine coated 24-well plates (4×105 cells/plate) in a basal
chemically-defined medium (BDM) [DMEM with 1 mg/ml bovine
serum albumin (BSA), 50 μg/ml apo-transferrin, 5 μg/ml insulin,
30 nM sodium selenite, 10 nM biotin, 10 nM hydrocortisone] plus
10 ng/ml of both PDGF and bFGF. The cells were maintained in BDM
and the medium was half-changed 3 times per week. For culturing
mature OLs, at day 7 OLs were changed to BDM plus 3,3′,5-triiodo-L-
thyronine (T3) (15 nM) and CNTF (10 ng/ml) and were half-changed
3 times per week for 2 weeks. At this stage, more than 95% of the cells
were MBP positive (Baud et al., 2004; Wang et al., 2004) and were
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Fig. 1. Inhibition of cPLA2, but not LOX, reduced the disease severity of EAE. A–C, At day 7 post immunization, mice were given AACOCF3, the cPLA2 inhibitor, AA861, the LOX inhibitor, and the combination of AACOCF3 and AA861 once a day
until day 28. Clinical scores in AACOCF3 treated group were significantly decreased from day 13 to day 28 when compared to the EAE-vehicle group (A). Treatment with AA861 did not attenuate the clinical scores (B). Co-administration of
AA861 and AACOCF3 did not further improve the protective effects afforded by AACOCF3 alone (C). *, pb0.05 was obtained when the AACOCF3 and AACOCF3 plus AA861 treated groups were compared to the EAE-vehicle group. D–G, Body
weight was significantly decreased in EAE and EAE-AA861 treated mice (D, E), but not in AACOCF3 and AACOCF3 plus AA861 treated mice (F, G) when compared with their respective control groups. *, pb0.05 was obtained when the EAE and
EAE-AA861 treated groups were compared to the mice given vehicle and AA861 control groups.
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used for the experiments. The contamination of astrocytes and
microglia was 1–2% each. For mixed cultures of microglia and OLs,
microglia were plated to 24-well plates containing mature OLs and
then used for further experiments.
Western blot analyses
At various time points after LPS treatment, microglia were lysed
with lysis buffer containing 20 mM Tris–HCl, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophos-
phate, 1 mM glycerolphosphate, 1 mM Na3VO4, and 1 mM phenyl-
methylsulfonyl fluoride. An aliquot of cell lysate was removed for later
protein determination. Cell lysate was mixed with Laemmli buffer,
boiled for 5 min, and stored at−20 °C. Equal amounts of protein were
separated by 4–12% SDS-PAGE and electrotransferred to a polyviny-
lidene difluoridemembrane.Membraneswere blockedwith 5% nonfat
milk in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h
and then incubated overnight at 4 °C with the primary antibodies
Fig. 2. Colocalization of cPLA2, 5-LOX and 12-LOX with mature OLs and neurons. A, Mature OLs immunostained with CC1 (green) were colocalized with cPLA2, 5-LOX and 12-LOX
(red) in the spinal cord white matter in mice without EAE induction. No difference was observed between the control and the EAE mice. Scale bars=50 μm. B, Neurons
immunostained with NeuN (green) were colocalized with cPLA2 and 12-LOX, but not with 5-LOX (red) in the spinal cord gray matter in control mice. The pattern of colocalization is
the same in both control and EAE mice. Scale bars=100 μm.
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against cPLA2 (Santa Cruz Biotechnology, Santa Cruz, CA), iNOS,
p47phox, p67phox (BD Biosciences Pharmingen) and nitrotyrosine
(Upstate Biotechnology, Lake Placid, NY) diluted at 1:1000 in TBST
containing 5% BSA. After washing 4 times with TBST, the membrane
was incubated for 1 h at room temperature with goat anti-rabbit and
goat anti-mouse horseradish peroxidase-conjugated secondary anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA) diluted at 1:2000.
The membranes were washed again as above and visualized by
enhanced chemiluminescence (ECL) according to the manufacturer's
protocol (PerkinElmer Life Sciences).
Immunocytochemistry and immunofluorescence microscopy
After treatments, cells were fixed with 4% paraformaldehyde in
PBS for 10 min at room temperature, washed three times with PBS,
and blocked with TBST (50 mM Tris–HCl, pH 7.4/150 mM NaCl/0.1%
Triton X-100) containing 5% goat serum for 1 h at room temperature.
The coverslips were incubated with mouse monoclonal antibodies
against cPLA2, p67phox, MBP and polyclonal antibody against F4/80
overnight at 4 °C. After three to four washes at 5 min each, the
appropriate secondary antibody conjugated with either Alexia Fluor
488 or Alexia Fluor 594 (Molecular Probes) was added to the
coverslips and incubated for 1 h. After three washes, the coverslips
were mounted onto glass slides with FluoroMount and kept dark at
4 °C. Cell images were captured with a fluorescence microscope
(Nikon Eclipse E800) equipped with a Nikon digital camera.
Nitrite measurement
The level of accumulated nitrite in themediumwas determined by
the Greiss reaction. Briefly, 50 μl of Greiss reagent (3.9 mM N-(1-
naphthyl)ethylenediamine/58 mM sulfanilamide/5% phosphoric
acid) was added to 50 μl of culture supernatant in a 96-well plate.
Absorbance was measured at 550 nm, and nitrite concentration was
calculated from a standard curve of sodium nitrite.
Measurement of intracellular ROS generation
Intracellular free radical generation was evaluated with DCF
(Molecular Probes, Eugene, OR) as we previously described (Wang
et al., 2004; Zhang et al., 2006). Briefly, after cells in 96-well plates
were treated with LPS in the absence or presence of AACOCF3 for 3 h,
they were then loaded with DCF (20 μM) for 30 min in Earle's
balanced salt solution (EBSS; 95% air/5% CO2, 37 °C). After the loading
solution was removed, cells in the wells were washed and incubated
in EBSS. The fluorescence of the cells in each well was measured and
recorded in the fluorescence plate-reader with excitation wavelength
at 480 nm and emission wavelength at 530 nm.
Toxicity assay
Survival of mature OLs was determined by counting MBP+ cells
with normal nuclei. Briefly, the mixed cultures of microglia and OLs
were treated with LPS (5 μg/ml) as specified in the figure legends for
48 h. After being washed with PBS and fixed with 4% paraformalde-
hyde, cells were immunostained with anti-MBP (Boehringer Mann-
heim, Indianapolis, IN) and anti-F4/80 (eBiosciences) antibodies. Five
random fields were counted in each coverslip under 20×
magnification.
Statistics
Cell densities in lumbar spinal cord white matter were manually
counted with areas measured using Nikon Elements software.
Statistical significance in vitro and in vivo assays was assessed using
ANOVA with the Tukey–Kramer post-hoc multiple comparison test.
Statistical analysis was performed using the Instat program from
GraphPad Software (San Diego, CA). Representative experiments are
shown unless noted otherwise. Experiments were performed with
triplicate samples, and the data are expressed as mean±SEM. All
experiments were repeated at least 3 times.
Results
Treatment with a PLA2 inhibitor, but not a LOX inhibitor, reduced the
severity of EAE
It is currently unclear how activation of LOX is involved in the
development of EAE. Although a LOX inhibitor has recently been
shown to delay the disease onset and the cumulative clinical scores of
Fig. 3. Expression of cPLA2 in T-lymphocytes andmacrophage/microglia in EAEmice. cPLA2 is expressed by T-lymphocytes (OX-52) andmacrophages/microglia (Mac-1) in EAEmice
at 2 weeks post immunization. Images shown are representative from four different animals in each group. Scale bars=25 μm.
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EAE, the maximal clinical score was not affected by the treatment
(Marusic et al., 2008). Moreover, similar to the results obtained from
COX-2 knockout (COX-2−/−) mice (Miyamoto et al., 2006), targeted
gene deletion of 5-LOX and 12-LOX does not affect, but actually
exacerbates the severity of EAE (Emerson and LeVine, 2004). To
further determine the role of 5-LOX or 12-LOX in the pathogenesis of
EAE, we treated EAE mice with AA861, the LOX inhibitor, AACOCF3,
the cPLA2 inhibitor, and the combination of both from day 7 post-
immunization. Consistent with the reports by others (Kalyvas et al.,
2009; Kalyvas and David, 2004; Marusic et al., 2005, 2008), AACOCF3
was found to significantly attenuate the clinical signs of EAE (Fig. 1A).
Although there was a trend of delayed onset of the symptoms,
significant differences were not reached when the clinical scores were
compared between the AA861 and the vehicle treated EAE mice
(Fig. 1B). Similarly, the combination of AA861 and AACOCF3 did not
exert more protective effects (Fig. 1C) than AACOCF3 itself (Fig. 1A). A
significantly decreased body weight was observed in the vehicle and
AA861 treatedmice, but not in the AACOCF3 treated EAE groupswhen
compared to their respective controls (Fig. 1D–G). These results
suggest that blocking the production of arachidonic acid, rather than
its downstream LOX metabolites, is effective against the disease
severity of EAE.
cPLA2 is highly expressed in T-lymphocytes and macrophages/microglia
in the spinal cord white matter of mice with EAE
Using cell type specific markers, we examined the expression of
cPLA2, 5-LOX and 12-LOX in the spinal cord mature OLs and neurons
in both EAE and control mice. Similar to the findings from a previous
report (Liu et al., 2006), we found that cPLA2 is expressed in both
CC1+ mature OLs (Fig. 2A) and NeuN+ neurons (Fig. 2B). While 12-
LOX was also shown to be expressed in both OLs and neurons, the
expression of 5-LOXwas seen in CC1+ OLs (Fig. 2A), but not in NeuN+
cells (Fig. 2B). When the expression was examined at 2 weeks
following EAE induction, a similar expression pattern was also
observed in EAE mice (data not shown). These results suggest that
cPLA2, 5-LOX and 12-LOX were not upregulated in these resident cells
of the spinal cord. Next, we assessed the expression of cPLA2 in
infiltrating T-lymphocytes and macrophages/microglia using OX-52
and Mac1 as the respective markers of these cell types. As shown in
Fig. 4. Treatment with AACOCF3 suppressed the increased expression of ALCAM in the EAE mouse spinal cord white matter. At 2 and 4 weeks post immunization, there was an
increase in the expression of ALCAM on endothelial cells in the EAE mouse spinal cord white matter as compared to the spinal cord vasculature of naïve animals. The increased
expression of ALCAM at both 2 weeks and 4 weeks seen in EAE-vehicle treated groups was dramatically reduced by treatment with AACOCF3. Nuclei stained with DAPI were shown
in blue, the expression of ALCAM in endothelium was shown in green, merged image reflected the colocalization of ALCAM with DAPI. Images shown are representative from four
different animals in each group.
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Fig. 3, cPLA2 is highly expressed in T-lymphocytes and macrophages/
microglia in EAE mice, but not in controls. These results suggest that
the increased expression of cPLA2 in lymphocytes and macrophages/
microglia might play an important role in the immune response of
EAE.
AACOCF3 preserved the integrity of blood–brain barrier after EAE
induction
During an MS/EAE exacerbation, T-cells infiltration and macro-
phages/microglia activation are facilitated by an increased perme-
ability of blood–brain barrier (BBB). To determine the integrity of BBB,
we assessed the expression of ALCAM in EAE mice spinal cord white
matter with/without treatment. ALCAM is now recognized as an
adhesion molecule involved in lymphocyte and macrophage infiltra-
tion across the BBB. The expression of ALCAM on BBB endothelial cells
has been shown to be upregulated by proinflammatory cytokines and
enhanced in EAE spinal cord homogenates and in human MS lesions
(Cayrol et al., 2008). Consistently, we found that the expression of
ALCAM in the ventral spinal cord white matter was increased in EAE
mice at 2 weeks and 4 weeks post-induction, and the increased
expression is reduced or diminished by treatment with AACOCF3
(Fig. 4). The same phenomenon was also found with ICAM-1, a well
characterized adhesion molecule expressed on inflamed BBB endo-
thelial cells (Alvarez et al., 2011; Chaudhary et al., 2006) (data not
shown). These results suggest that treatment with AACOCF3 may
preserve the BBB integrity in EAE mice.
Treatment with AACOCF3 alone or in combination with AA861
completely prevented the loss of mature OLs and the axonal injury
A significant loss of mature OLs was found at 28 days following
EAE induction in the spinal cord white matter of the vehicle treated
mice (Fig. 5). The number of mature OLs in the EAE vehicle treated
animals was 290±85 cells/mm2, which was significantly less than
the number of mature OLs in controls (750±180 cells/mm2, pb0.05).
In AACOCF3 alone and its combinationwith AA861 treated groups, the
numbers of mature OLs increased to 650±37 cells/mm2 and 655±86
cells/mm2, respectively. The density of mature OLs in these groups is
significantly higher (pb0.05) than the non-treated EAE group, and is
similar to that of the control groups. On the other hand, treatment
with AA861 did not prevent the loss of mature OLs. The density of OLs
Fig. 5. Treatment with AACOCF3, but not AA861, completely blocked the loss of mature
OLs in the EAE mouse spinal cord white matter. At 28 days post immunization, the
density of mature OLs in the spinal cord white matter of EAE mice was significantly less
than that found in the control animals. The loss of mature OLs was prevented by the
administration of AACOCF3 alone or its combination with AA861, but not by the
treatment with AA861. *, pb0.05 was obtained when the EAE-vehicle and EAE-AA861
treated groups were compared to the respective control groups. Increased density of
OLs were found in AACOCF3 treated groups compared with EAE-vehicle group
(^, pb0.05). The representative image showing the CC1+ mature OLs in control, EAE
and AACOCF3 treated mouse spinal cord white matter was shown. Scale bar=50 μm.
Fig. 6. Treatmentwith AACOCF3, but not AA861, attenuated axonal injury in the spinal cordwhite matter of EAEmice. At 28 days post immunization, the density of NF200+ (A), and SMI
32+ (B) axonswas assessed in the spinal cordwhitematter of EAEmicewith andwithout treatments. The overall density of axons labeledwith NF200, which labels both phosphorylated
and non-phosphorylated neurofilaments, in the spinal cord white matter was not significantly different between EAE-vehicle, control and the drug treated groups (A). SMI-32+ axons,
which detect the dephosphorylated neurofilaments, were significantly increased in EAE-vehicle and EAE-AA861 treated mice compared to the control group (*, pb0.05). Less SMI-32
staining was shown in AACOCF3 treated groups compared to EAE-vehicle group (^, pb0.05) (B). The results shown are pooled from 6 different animals in each group.
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in the AA861 treated group was 400±38 cells/mm2, which was
similar in the untreated EAE animals.
To determinewhether the drug treatment could affect axonal injury,
the number of NF200+ axons in spinal cord white matter was counted.
Although therewasa trendof reductionofNF200+axons in EAE-vehicle
group, the overall density of NF200+ axons was not significantly
different in the control and the EAE groups regardless of the drug
treatments (Fig. 6A). Because NF-200 can detect both phosphorylated
and non-phosphorylated axonal neurofilaments, the differences in the
number of non-/de-phosphorylated axons among these groups might
bemasked, unless thedephosphorylated axons can be rapidly degraded.
However, SMI-32, which detects dephosphorylated neurofilaments, is
an indicator of axonal injury in MS and EAE (Trapp et al., 1998). We
found that the density of SMI-32+ axons was significantly increased in
vehicle andAA861 treated EAE groups. Treatmentwith AACOCF3, or the
combination of AACOCF3 and AA861, remarkably reduced the number
of SMI-32+ axons (Fig. 6B). Similarly, increased β-APP immunoreactiv-
ity in spinal cord white matter was also reduced by treatment with
AACOCF3 (data not shown). Taken together, these results suggest that
treatment with AACOCF3, but not AA861, can prevent demyelination
and axonal injury in mice after EAE induction.
AACOCF3 attenuated nitrotyrosine formation in the EAE mouse spinal
cord white matter
Peroxynitrite, the highly toxic reaction product of nitric oxide and
superoxide (Beckman and Koppenol, 1996), has been shown to
contribute to the pathology found in EAE/MS (Hooper et al., 1997; Liu
et al., 2001; Spitsin et al., 2001). To support this notion, scavengers or the
decomposition catalysts of peroxynitrite are found to be efficacious in
the treatment of EAE (Bolton et al., 2008; Cross et al., 2000;Hooper et al.,
1998, 2000). Here we testedwhether the protective effects of AACOCF3
can be, at least in part, due to its inhibition of peroxynitrite formation.
Using nitrotyrosine immunostaining, a marker for peroxynitrite
formation, we found nitrotyrosine immunoreactivity was dramatically
increased in theEAEmouse spinal cordwhitematter (Fig. 7), and almost
completely blockedby the treatmentwithAACOCF3. This result strongly
suggests that AACOCF3 may protect OLs and axons from injury via
blocking peroxynitrite formation.
AACOCF3 blocked peroxynitrite formation in LPS-activated microglia and
reactive microglia induced toxicity to mature OLs
We and others have previously shown that peroxynitrite is the
major toxic species released from reactive microglia causing toxicity
to neurons andmature OLs (Li et al., 2005; Xie et al., 2002; Zhang et al.,
2004, 2006). To test whether AACOCF3 can affect the production of
peroxynitrite in reactive microglia, generation of nitric oxide and
superoxide was examined in LPS activated microglia in the presence
of AACOCF3. LPS at 1 μg/ml induced upregulation of cPLA2, iNOS and
components of the NADPH oxidase complex, p47phox and p67phox,
in a time-dependent manner. At 6–8 h following LPS treatment, the
expression of cPLA2, iNOS, p47phox and p67phox was dramatically
increased (Fig. 8A). Following 24 h LPS treatment, cPLA2 and p67phox
were found to be translocated to the plasma membrane (Fig. 8B),
indicating that cPLA2 and NADPH oxidase are activated in LPS-
activated microglia. AACOCF3 at 10 μM attenuated upregulation of
iNOS and p67phox in LPS activated microglia (Fig. 8C) and generation
of nitric oxide and superoxide (Fig. 8D–E). In mixed cultures of
microglia and mature OLs, LPS (5 μg/ml) caused toxicity to OLs, but
not to microglia (Fig. 9). Similar to the effects of the peroxynitrite
decomposition catalyst FeTMPyP, AACOCF3 also significantly attenu-
ated cell death triggered by reactive microglia (Fig. 9). These results
suggested that the protective effects of AACOCF3 might be attribut-
able to its blockade of peroxynitrite formation.
Discussion
Inhibition of PLA2 has been shown to be effective for the treatment
of EAE (Kalyvas et al., 2009; Kalyvas and David, 2004; Marusic et al.,
2005, 2008). However, the protective mechanisms of the pharmaco-
logical PLA2 inhibitors are still unclear. In the present study, we found
that administration of AACOCF3 after EAE induction reduced clinical
scores and the typical weight loss of EAE mice. AACOCF3 markedly
attenuated the loss of mature OLs and the injury to axons typically
found in EAE. The protective effects of AACOCF3 are likely due to its
improvement of the BBB integrity, its reduction of infiltrating
leukocytes, and its inhibition of nitrotyrosine formation in the spinal
cord white matter. In primary cultures of microglia, AACOCF3
attenuated iNOS induction, nitric oxide production and the generation
of superoxide. Similar to the protective effect of FeTMPyP, a
decomposition catalyst of peroxynitrite, AACOCF3 also significantly
attenuated the toxicity of mature OLs triggered by reactive microglia.
Deregulation of lipid metabolism has been implicated in many
inflammatory and neurodegenerative diseases, including MS, stroke,
traumatic brain and spinal cord injury, and Alzheimer's disease
(Adibhatla and Hatcher, 2008). Due to the high lipid contents in the
central nervous system (CNS), hydrolysis of membrane phospholipids
catalyzed by PLA2 might be important for initiation and progression of
the aforementioned diseases. Although iPLA2 and sPLA2 are able to
liberate arachidonic acids from membrane phospholipids (Balsinde
and Balboa, 2005; Kudo and Murakami, 2002; Wijewickrama et al.,
Fig. 7. Treatment with AACOCF3 significantly reduced nitrotyrosine immunoreactivity in the EAE mouse spinal cord white matter. Nitrotyrosine immunostaining, indicative of
peroxynitrite formation, in the spinal cord white matter was dramatically increased in the EAE mice and almost completely blocked by treatment with AACOCF3 at 2 weeks post
immunization. The images are representative of 6 different animals in each group.
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2006a,b), cPLA2α is thought to be the primary and the only isoform to
selectively cleave arachidonyl phospholipids liberating arachidonic
acids (Kita et al., 2006; Kudo and Murakami, 2002). The released
arachidonic acids are in turn converted to prostaglandins and
leukotrienes via activation of the COX and LOX pathways, respective-
ly. These proinflammatory eicosanoids have long been suggested to
contribute to the pathology of EAE (Bolton et al., 1984; Prosiegel et al.,
1989; Reder et al., 1995), but the results obtained using pharmaco-
logical and genetic approaches are rather controversial. It has been
shown that several COX and LOX inhibitors can reduce the severity of
EAE (Marusic et al., 2008; Muthian et al., 2006; Ni et al., 2007; Ospelt
et al., 2008). However, COX2−/− mice are found to develop EAE
similar to the wild type controls (Miyamoto et al., 2006), and the
disease severity is exacerbated in both 12-LOX−/− and 5-LOX−/−
animals (Emerson and LeVine, 2004). The fact that rofecoxib, a COX
inhibitor, was withdrawn due to its severe side effects in MS patients
(Juni et al., 2004) suggests that inhibition of the COX pathway would
not be clinically useful for the treatment ofMS (James et al., 2007). It is
also possible that inhibition of COX renders arachidonic acids to shift
towards the LOX metabolic pathway, which can mediate OL toxicity
and axonal injury. In addition to producing arachidonic acids,
activation of cPLA2 also generates lysophosphatidylcholine and
platelet-activating factors causing inflammation and demyelination
in MS (Kihara et al., 2005; Kihara et al., 2008). All these findings
indicate that cPLA2 may be a better target for EAE treatment. Indeed,
we found that AACOCF3, the cPLA2 inhibitor, but not AA861, the LOX
inhibitor, reduced the severity of clinical symptoms in EAE. Addition
of AA861 did not alter the protective effects of AACOCF3. In contrast to
the recent report that ziluton, a 5-LOX inhibitor, delays EAE onset, but
not the maximal severity of EAE (Marusic et al., 2008), we found
Fig. 8. AACOCF3 attenuated iNOS induction and ROS generation in LPS-activated microglia. A, Microglia were treated with LPS (1 μg/ml) for various times and then lysed forWestern
blot analysis. The expression of cPLA2, iNOS, p47phox (p47) and p67phox (p67) was upregulated by LPS in a time-dependent manner. At 6 and 8 h following LPS treatment, a
dramatic increase of these proteins in reactive microglia was observed. A representative experiment of 3 that were performed is shown. B, At 24 h following LPS treatment, microglia
were fixed and immunostained with monoclonal antibodies against cPLA2 and p67. Both cPLA2 and p67 were translocated to the plasma membrane after LPS treatment. The
representative image from 4 different experiments is shown. C, Microglia were treated with LPS (1 μg/ml) for 24 h and then lysed for Western blot analysis. The expression of iNOS
and p67was upregulated by LPS and attenuated by the treatment with AACOCF3 (10 μM). AAC represents AACOCF3. A representative experiment of 3 that were performed is shown.
D, The production of nitric oxide was significantly increased in microglia treated with LPS (1 μg/ml) for 24 h and completely blocked by AACOCF3 (AAC, 10 μM). ***, pb0.001 was
obtained when LPS alone group was compared to control and AACOCF3 treated groups. A representative experiment of 3 that were performed is shown. E, Microglia were treated
with LPS (1 μg/ml) for 3 h and then incubated with DCF for 30 min. The increased fluorescence intensity, indicative of ROS generation, was measured. AACOCF3 (AAC, 10 μM)
significantly reduced ROS generation in LPS treated microglia. ***, pb0.001 was obtained when LPS alone group was compared to control and AACOCF3 treated groups. A
representative experiment of 3 that were performed is shown.
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AA861 neither affected the disease onset nor the maximal severity,
although there was a trend for reduced clinical scores at the early
onset of the disease. The similar result was also found when baicalein,
a 12/15-LOX inhibitor (van Leyen et al., 2006), was administered
(data not shown). It is unclear what causes the differences, but the
factors may include the different dosages, routes of administration,
and the characteristics of these inhibitors. It is shown that the
protection afforded by the LOX inhibitor in the previous report is
found to be much less than the COX and cPLA2 inhibitors (Marusic
et al., 2008).
Although EAE is known to be a T cell-mediated disease,
macrophage and microglia are likely the effecter cells causing toxicity
to OLs, demyelination and axonal injury. Several studies have
previously reported that PLA2 inhibition can diminish the Th1 and
Th17 response and the production of inflammatory cytokines and
chemokines (Bettelli et al., 2007; Kalyvas and David, 2004; Marusic
et al., 2008), however, the role of PLA2 on the function of the
infiltrating macrophage and the activated microglia in EAE are largely
unknown. Similar to the findings by others (Kalyvas et al., 2009;
Kalyvas and David, 2004), we found that the expression of cPLA2 is
elevated in macrophage and microglia in the EAE mouse spinal cord
white matter. Although cPLA2 is also expressed in neurons and OLs,
the differences of its expression in these cell types were not found
between the EAE and control animals. Consistent with the reports that
peroxynitrite may be an important contributor to the development of
EAE (Hooper et al., 1997; Liu et al., 2001; Spitsin et al., 2001), we
found that nitrotyrosine immunoreactivity was dramatically in-
creased in the spinal cord white matter of EAE mice and almost
completely blocked by treatment with AACOCF3. Similarly, we found
AACOCF3 attenuated iNOS induction, the upregulation and translo-
cation of p47phox and p67phox in LPS activated microglia. Since
NADPH oxidase is believed to be the major enzyme for superoxide
production in reactive microglia (Block et al., 2007; Li et al., 2005; Qin
et al., 2004; Sun et al., 2007; Xie et al., 2002), these results suggest that
AACOCF3 can attenuate the generation of nitric oxide and superoxide,
and even more importantly, their highly toxic reaction product
peroxynitrite. Furthermore, we found that similar to the protective
effects of the decomposition catalyst of peroxynitrite, AACOCF3
significantly attenuated the toxicity of mature OLs triggered by
reactivemicroglia, suggesting the protective action of AACOCF3 in EAE
mice might be due to its inhibition of peroxynitrite formation by
reactive microglia in the spinal cord white matter. Alternatively,
AACOCF3 may produce immunomodulatory effects on peripheral
leukocytes, thus inhibiting extravasation of these immune cells into
the CNS parenchyma. This is at least partially supported by our
findings that treatment with AACOCF3 preserves the BBB integrity in
EAE mice.
It is known that AACOCF3 not only inhibits cPLA2, but also inhibits
iPLA2 and COX-2 (Ghomashchi et al., 1999; Kalyvas and David, 2004).
Recently, it has been shown that the inhibitors of cPLA2, iPLA2 and
sPLA2 can all reduce the severity of EAE, and activation of different
PLA2 isoforms may be involved in the different stages of the disease
(Kalyvas et al., 2009). However, except for cPLA2α, the role of iPLA2
and sPLA2 in the development of EAE has not been validated by using
genetic approaches. Nevertheless, these studies may help to develop
isoform specific PLA2 inhibitors for the treatment of EAE, and more
importantly may offer valuable therapeutics for MS.
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